ישראל - עברית - Ministry of Health

bioavenir ltd, israel - ampicillin as sodium salt; sulbactam as sodium salt - אבקה להכנת תמיסה לזריקה - ampicillin as sodium salt 2000 mg; sulbactam as sodium salt 1000 mg - sulbactam

ישראל - עברית - Ministry of Health

tec-o-pharm-libra ltd - tranexamic acid - תמיסה להזרקה - tranexamic acid 500 mg / 5 ml - tranexamic acid

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

ישראל - עברית - Ministry of Health

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ישראל - עברית - Ministry of Health

mediline ltd. - methylphenidate hydrochloride 20 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

ישראל - עברית - Ministry of Health

mediline ltd. - methylphenidate hydrochloride 30 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient.treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

ישראל - עברית - Ministry of Health

mediline ltd. - methylphenidate hydrochloride 40 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.